TransCode Therapeutics (NASDAQ:RNAZ) announced that the National Institutes of Health (NIH) has awarded the company a $2 million Direct to Phase II Small Business Innovation Research grant to support the clinical evaluation of its lead therapeutic candidate, TTX-MC138.
TransCode recently initiated a Phase I/II clinical trial of TTX-MC138 for the treatment of advanced solid tumors.
A first-in-class therapeutic candidate, TTX-MC138 shows promising potential in addressing metastatic disease. Its successful clinical development could offer a new treatment option for many patients with metastatic cancer.
“We are honored that the NIH recognizes and continues to support our mission to advance therapies against metastatic cancer,” said Zdravka Medarova, Ph.D., CSO of TransCode. “NIH funding is awarded only after rigorous review. We believe that this award attests to the potential impact, novelty, and robustness of the TTX-MC138 clinical development program.”
